By Billy Candra 
This groundbreaking research, published in Nature Communications, details a novel approach to intercept cancer development at its earliest stages, specifically targeting sonic hedgehog (SHH) medulloblastoma. The findings from a team led by Dr. Peter Dirks, a Senior Scientist in the Developmental, Stem Cell & Cancer Biology program and Chief of the Division of Neurosurgery at SickKids, offer a significant leap forward in understanding and potentially treating aggressive pediatric brain tumours, which traditionally present formidable challenges for medical researchers and clinicians.
The Intricacies of Childhood Brain Cancer: A Formidable Foe
Brain cancer in children remains a devastating diagnosis, carrying with it a unique set of complexities that distinguish it from adult malignancies. Medulloblastoma, accounting for roughly 20% of all childhood brain tumours, is the most prevalent malignant variant. It originates in the cerebellum, the part of the brain responsible for coordination and balance. While advancements in surgery, radiation therapy, and chemotherapy have improved survival rates for some subtypes, these aggressive treatments often come with severe, long-term neurocognitive and physical side effects, particularly in the developing brains of young patients. The goal of modern pediatric oncology research is not only to cure but also to minimize the burden of treatment.
A key challenge in treating brain cancers lies in their insidious nature. Symptoms often manifest only when tumours have grown considerably, becoming highly complex and heterogeneous. By this stage, the fundamental mechanisms that initiated and drove the tumour’s growth are frequently obscured, making targeted therapies difficult to develop and implement effectively. The blood-brain barrier further complicates drug delivery, limiting the efficacy of many systemic treatments. This necessitates innovative strategies that can identify and disrupt tumour pathways at their very inception, ideally before significant cellular damage or metastasis occurs.
Unmasking the Role of Cancer Stem Cells in SHH Medulloblastoma
The research by Dr. Dirks’ team focuses on sonic hedgehog (SHH) medulloblastoma, one of the four molecular subgroups of the disease, which is particularly common in infants and young children. This subtype is characterized by dysregulation in the SHH signaling pathway, a crucial developmental pathway that, when aberrantly activated, can drive uncontrolled cell proliferation. Within these tumours, a population of ‘sleeping’ stem cells plays a critical role. These cancer stem cells (CSCs) are a small subpopulation of cells within a tumour that possess self-renewal capabilities and can differentiate into various cell types found in the tumour mass. They are often resistant to conventional therapies, contributing to tumour recurrence and metastasis. Understanding how these dormant cells ‘wake up’ and initiate tumour formation or drive relapse after treatment is paramount.
The SickKids team embarked on a detailed investigation into the cellular transitions that underpin the development of SHH medulloblastoma. Their intensive genomic and functional studies revealed a critical protein, OLIG2, as a central orchestrator in this process. OLIG2, a transcription factor normally involved in oligodendrocyte development in the central nervous system, was found to activate these quiescent stem cells, prompting them to divide and proliferate, thereby initiating tumour formation or facilitating regrowth after initial therapy. This discovery represents a pivotal insight, as it identifies a specific molecular ‘switch’ that can be targeted to prevent tumour progression.
"Our findings offer a novel strategy to target cancer stem cells, providing hope for more effective treatments against aggressive brain tumors," emphasizes Dr. Dirks, highlighting the potential paradigm shift this discovery could bring to pediatric neuro-oncology.
Cancer Interception: A New Therapeutic Frontier
The concept of "cancer interception" lies at the heart of this breakthrough. Rather than solely focusing on eradicating established tumours, this approach aims to prevent tumour growth before it becomes clinically significant or to halt its re-emergence after initial treatment. The researchers identified a crucial "window of opportunity" during these early cellular transitions where tumour progression could be effectively blocked.
Building upon this understanding, the team investigated therapeutic strategies to disrupt the OLIG2 protein’s activity. They identified a small molecule inhibitor, CT-179, which specifically targets and disrupts the function of OLIG2. In preclinical models of SHH medulloblastoma, the results were compelling. When CT-179 was administered in combination with a previously established conventional treatment, it successfully targeted the residual stem cells that often survive initial therapies. By preventing these stem cells from re-awakening and reactivating, the treatment effectively inhibited tumour relapse. This is a crucial finding, as relapse remains a major cause of mortality in pediatric brain cancers.
Furthermore, for early-stage SHH medulloblastoma, the administration of CT-179 alone demonstrated remarkable efficacy. It prevented the formation of tumours altogether and significantly increased survival rates in the preclinical models. This dual benefit—preventing both initial tumour formation and post-treatment relapse—underscores the profound potential of this interception strategy.
Dr. Kinjal Desai, the first author of the study and a postdoctoral researcher in the Dirks lab, articulates the elegance of this approach: "There is order to how the cancer initiating stem cells undergo fate changes to form tumours. We can target an early transition event and intercept the entire process – essentially stopping the cancer in its earliest form." This statement encapsulates the core principle of the research: identifying and disrupting the earliest, most fundamental drivers of oncogenesis.
Corroboration and Broader Implications: A Collaborative Effort
The significance of the SickKids team’s findings is further amplified by a parallel study published simultaneously in Nature Communications. This independent research, conducted by colleagues at Children’s Healthcare of Atlanta and QIMR Berghofer Medical Research Institute in Australia, corroborated the role of OLIG2 and the efficacy of similar interception strategies. Such independent validation is critical in scientific research, strengthening the robustness and generalizability of the findings.
Importantly, these collaborative studies also suggest that this OLIG2-targeting approach may not be limited to SHH medulloblastoma. Early indications suggest potential applicability to other aggressive brain cancers, including diffuse intrinsic pontine glioma (DIPG). DIPG is an extremely aggressive and uniformly fatal brain tumour primarily affecting children, for which there are currently no effective treatments. The possibility of extending this therapeutic strategy to DIPG offers a glimmer of hope in a disease area desperately in need of breakthroughs.
This latest research from the Dirks Lab also complements their recent work published in Nature, which elucidated the early stages of glioblastoma development, another highly aggressive adult brain tumour. This continuous stream of high-impact research from Dr. Dirks and his team, based within the Arthur and Sonia Labatt Brain Tumour Research Centre (BTRC) at SickKids, underscores their leading role in understanding the fundamental biology of brain cancer and translating these insights into potential therapies.
Charting the Future: From Preclinical Success to Clinical Impact
While the preclinical results are highly promising, the journey from laboratory discovery to widespread clinical application is often long and arduous. The next critical step will involve translating these findings into human clinical trials. This will entail a phased approach, starting with Phase 1 trials to assess safety and optimal dosing in a small group of patients, followed by larger Phase 2 and Phase 3 trials to evaluate efficacy against standard treatments.
The researchers envision that this OLIG2-targeted "magic bullet" could be particularly beneficial for specific patient populations. This includes children diagnosed with SHH medulloblastoma who are at high risk of relapse after conventional treatments, as well as those who are being monitored for recurrence. The ability to intercept tumour regrowth before it becomes clinically apparent would dramatically alter the prognosis for these children.
Beyond treatment, the diagnostic potential of this discovery is immense. Dr. Dirks highlights the move towards "precision biology." "At SickKids, we’re already genetically testing every child with cancer to inform their diagnosis and treatments – our study goes beyond genetic testing to precision biology," he explains. This implies that future diagnostic tests could go beyond simply identifying genetic mutations to understanding the precise biological pathways and cellular states that drive a child’s specific cancer.
Imagine a future where children identified as being at high genetic risk for SHH medulloblastoma could undergo regular monitoring for early signs of OLIG2 activation. If detected, an intervention like CT-179 could potentially be administered preventatively, stopping the cancer from ever developing into a full-blown tumour. This proactive, preventative approach represents a transformative vision for pediatric cancer care, shifting the paradigm from treating established disease to intercepting it before it gains a foothold.
The research has been made possible through the generous support of numerous organizations dedicated to advancing cancer research, including the Canadian Institutes of Health Research (CIHR), Ontario Institute for Cancer Research, Terry Fox Research Institute, Canadian Cancer Society, Cancer Research UK, Stand Up to Cancer, Jessica’s Footprint Foundation, Hopeful Minds Foundation, b.r.a.i.n.child, Meagan’s Walk, Garron Family Cancer Centre, the Bresler family, and SickKids Foundation. This broad base of funding underscores the collaborative spirit and societal commitment required to tackle such complex and critical medical challenges.
The discovery by the SickKids team represents a significant stride towards a future where the most common childhood malignant brain cancer, and potentially others, can be not just treated, but intercepted and prevented, offering a new beacon of hope for countless children and their families worldwide.
